A Glimpse into the Pathophysiology, Classification, Clinical Presentations, and Management of Psoriasis

Document Type : Review Article

Authors

1 Medicinal Plants Processing Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

2 Department of Phytopharmaceuticals (Traditional Pharmacy), School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

3 Department of Clinical Pharmacy, School of Pharmacy, Shiraz University of Medical Sciences, Shiraz, Iran

10.30476/tips.2025.106092.1288

Abstract

The skin and dermatological diseases have a considerable potential to impact a person's social conduct, self-esteem, and willingness to engage in social interactions. The burden of skin diseases includes both their high incidence and the long-term morbidity associated with them. Psoriasis is the most prevalent immune-mediated inflammatory disease worldwide and is a multifactorial skin condition that arises from the interaction of immunological, genetic, and environmental factors. Numerous comorbidities, such as psoriatic arthritis, inflammatory bowel disease, metabolic syndromes, and complications related to respiratory, cardiovascular, and mental health, are associated with chronic psoriasis. There are several forms of cutaneous psoriasis. Psoriasis vulgaris is the most common phenotype, accounting for about 85–90% of psoriasis cases. Based on the clinical severity of the lesions, patients with psoriatic disease can be categorized as having mild, moderate, or severe disease. This review highlights various psoriasis presentations, related clinical signs and symptoms, and the available treatment options.

Highlights

Dena Firouzabadi (Google Scholar)

Mohammad M. Zarshenas (Google Scholar)

Keywords

References

1.    Chen WY, Chen SC, Hsu SY, Lin YA, Shih CM, Huang CY, Wang KH, Lee AW. Annoying Psoriasis and Atopic Dermatitis: A Narrative Review. Int J Mol Sci. 2022 Apr 28;23(9):4898. doi: 10.3390/ijms23094898. PMID: 35563285; PMCID: PMC9104570.
2.    Sanclemente G, Burgos C, Nova J, Hernández F, González C, Reyes MI, et al. The impact of skin diseases on quality of life: A multicenter study. Actas Dermosifiliogr. 2017 Apr;108(3):244-252. English, Spanish. doi: 10.1016/j.ad.2016.11.008. Epub 2017 Jan 4. PMID: 28063525.
3.    Flohr C, Hay R. Putting the burden of skin diseases on the global map. Br J Dermatol. 2021 Feb;184(2):189-190. doi: 10.1111/bjd.19704. PMID: 33544440.
4.    Parisi R, Symmons DP, Griffiths CE, Ashcroft DM; Identification and Management of Psoriasis and Associated ComorbidiTy (IMPACT) project team. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013 Feb;133(2):377-85. doi: 10.1038/jid.2012.339. Epub 2012 Sep 27. PMID: 23014338.
5.    Michalek IM, Loring B, John SM. A systematic review of worldwide epidemiology of psoriasis. J Eur Acad Dermatol Venereol. 2017 Feb;31(2):205-212. doi: 10.1111/jdv.13854. Epub 2016 Aug 30. PMID: 27573025.
6.    Rajguru JP, Maya D, Kumar D, Suri P, Bhardwaj S, Patel ND. Update on psoriasis: A review. J Family Med Prim Care. 2020 Jan 28;9(1):20-24. doi: 10.4103/jfmpc.jfmpc_689_19. PMID: 32110559; PMCID: PMC7014874.
7.    Armstrong AW, Mehta MD, Schupp CW, Gondo GC, Bell SJ, Griffiths CEM. Psoriasis Prevalence in Adults in the United States. JAMA Dermatol. 2021 Aug 1;157(8):940-946. doi: 10.1001/jamadermatol.2021.2007. PMID: 34190957; PMCID: PMC8246333.
8.    Kimmel GW, Lebwohl M. Psoriasis: Overview and Diagnosis. Evidence-Based Psoriasis. 2018 Jul 1:1–16. doi: 10.1007/978-3-319-90107-7_1. PMCID: PMC7122924.
9.    Rachakonda TD, Schupp CW, Armstrong AW. Psoriasis prevalence among adults in the United States. J Am Acad Dermatol. 2014 Mar;70(3):512-6. doi: 10.1016/j.jaad.2013.11.013. Epub 2014 Jan 2. PMID: 24388724.
10.    Garshick MK, Kimball AB. Psoriasis and the life cycle of persistent life effects. Dermatol Clin. 2015 Jan;33(1):25-39. doi: 10.1016/j.det.2014.09.003. PMID: 25412781.
11.    Ogawa K, Okada Y. The current landscape of psoriasis genetics in 2020. J Dermatol Sci. 2020 Jul;99(1):2-8. doi: 10.1016/j.jdermsci.2020.05.008. Epub 2020 May 28. PMID: 32536600.
12.    Capon F. The Genetic Basis of Psoriasis. Int J Mol Sci. 2017 Nov 25;18(12):2526. doi: 10.3390/ijms18122526. PMID: 29186830; PMCID: PMC5751129.
13.    Wu M, Dai C, Zeng F. Cellular Mechanisms of Psoriasis Pathogenesis: A Systemic Review. Clin Cosmet Investig Dermatol. 2023 Sep 14;16:2503-2515. doi: 10.2147/CCID.S420850. PMID: 37727872; PMCID: PMC10506593.
14.    Yamanaka K, Yamamoto O, Honda T. Pathophysiology of psoriasis: A review. J Dermatol. 2021 Jun;48(6):722-731. doi: 10.1111/1346-8138.15913. Epub 2021 Apr 22. PMID: 33886133.
15.    Hugh JM, Weinberg JM. Update on the pathophysiology of psoriasis. Cutis. 2018 Nov;102(5S):6-12. PMID: 30566550.
16.    Zachariae C, Skov L. Obesity as a risk factor for psoriasis. J Eur Acad Dermatol Venereol. 2020 May;34(5):915-916. doi: 10.1111/jdv.16434. PMID: 32441426.
17.    Jensen P, Skov L. Psoriasis and Obesity. Dermatology. 2016;232(6):633-639. doi: 10.1159/000455840. Epub 2017 Feb 23. PMID: 28226326.
18.    Fleming P, Kraft J, Gulliver WP, Lynde C. The Relationship of Obesity With the Severity of Psoriasis: A Systematic Review. J Cutan Med Surg. 2015 Sep-Oct;19(5):450-6. doi: 10.1177/1203475415586332. Epub 2015 May 7. PMID: 26271963.
19.    Pezzolo E, Naldi L. The relationship between smoking, psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2019 Jan;15(1):41-48. doi: 10.1080/1744666X.2019.1543591. Epub 2018 Nov 6. PMID: 30380949.
20.    Fortes C, Mastroeni S, Leffondré K, Sampogna F, Melchi F, Mazzotti E, et al. Relationship between smoking and the clinical severity of psoriasis. Arch Dermatol. 2005 Dec;141(12):1580-4. doi: 10.1001/archderm.141.12.1580. PMID: 16365261.
21.    Armstrong AW, Harskamp CT, Dhillon JS, Armstrong EJ. Psoriasis and smoking: a systematic review and meta-analysis. Br J Dermatol. 2014 Feb;170(2):304-14. doi: 10.1111/bjd.12670. PMID: 24117435.
22.    Thorleifsdottir RH, Eysteinsdóttir JH, Olafsson JH, Sigurdsson MI, Johnston A, Valdimarsson H, et al. Throat Infections are Associated with Exacerbation in a Substantial Proportion of Patients with Chronic Plaque Psoriasis. Acta Derm Venereol. 2016 Aug 23;96(6):788-91. doi: 10.2340/00015555-2408. PMID: 26984718; PMCID: PMC4995120.
23.    Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk Factors for the Development of Psoriasis. Int J Mol Sci. 2019 Sep 5;20(18):4347. doi: 10.3390/ijms20184347. PMID: 31491865; PMCID: PMC6769762.
24.    Lee EB, Wu KK, Lee MP, Bhutani T, Wu JJ. Psoriasis risk factors and triggers. Cutis. 2018 Nov;102(5S):18-20. PMID: 30566552.
25.    Basavaraj KH, Ashok NM, Rashmi R, Praveen TK. The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol. 2010 Dec;49(12):1351-61. doi: 10.1111/j.1365-4632.2010.04570.x. PMID: 21091671.
26.    Balak DM, Hajdarbegovic E. Drug-induced psoriasis: clinical perspectives. Psoriasis (Auckl). 2017 Dec 7;7:87-94. doi: 10.2147/PTT.S126727. PMID: 29387611; PMCID: PMC5774610.
27.    Alharbi NS, Almami IS. Activation and upregulation of keratinocyte and epidermal transglutaminases are associated with depletion of their substrates in psoriatic lesions. Eur Rev Med Pharmacol Sci. 2023 Dec 1;27(23). doi: 10.26355/eurrev_202312_34567.
28.    Yan BX, Chen XY, Ye LR, Chen JQ, Zheng M, Man XY. Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction. Front Med (Lausanne). 2021 Oct 13;8:649408. doi: 10.3389/fmed.2021.649408. PMID: 34722555; PMCID: PMC8548430.
29.    Raharja A, Mahil SK, Barker JN. Psoriasis: a brief overview. Clin Med (Lond). 2021 May;21(3):170-173. doi: 10.7861/clinmed.2021-0257. PMID: 34001566; PMCID: PMC8140694.
30.    Griffiths CE, Christophers E, Barker JN, Chalmers RJ, Chimenti S, Krueger GG, Leonardi C, Menter A, Ortonne JP, Fry L. A classification of psoriasis vulgaris according to phenotype. Br J Dermatol. 2007 Feb;156(2):258-62. doi: 10.1111/j.1365-2133.2006.07675.x. PMID: 17223864.
31.    Sarac G, Koca TT, Baglan T. A brief summary of clinical types of psoriasis. North Clin Istanb. 2016 Jun 14;3(1):79-82. doi: 10.14744/nci.2016.16023. PMID: 28058392; PMCID: PMC5175084.
32.    Dhabale A, Nagpure S. Types of Psoriasis and Their Effects on the Immune System. Cureus. 2022 Sep 24;14(9):e29536. doi: 10.7759/cureus.29536. PMID: 36312680; PMCID: PMC9592057.
33.    Zhou T, Koussiouris J, Kim L, Vender R. Management of Guttate Psoriasis: A Systematic Review. J Cutan Med Surg. 2024 Nov-Dec;28(6):577-584. doi: 10.1177/12034754241266187. Epub 2024 Jul 30. PMID: 39080843; PMCID: PMC11619194.
34.    Leung AK, Barankin B, Lam JM, Leong KF. Childhood guttate psoriasis: an updated review. Drugs Context. 2023 Oct 23;12:2023-8-2. doi: 10.7573/dic.2023-8-2. PMID: 37908643; PMCID: PMC10615329.
35.    Pfingstler LF, Maroon M, Mowad C. Guttate psoriasis outcomes. Cutis. 2016 Feb;97(2):140-4. PMID: 26919501.
36.    Bachelez H. Pustular Psoriasis: The Dawn of a New Era. Acta Derm Venereol. 2020 Jan 30;100(3):adv00034. doi: 10.2340/00015555-3388. PMID: 31971600; PMCID: PMC9128889.
37.    Menter A, Van Voorhees AS, Hsu S. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options. Dermatol Ther (Heidelb). 2021 Dec;11(6):1917-1929. doi: 10.1007/s13555-021-00612-x. Epub 2021 Oct 9. PMID: 34626330; PMCID: PMC8611132.
38.    Marrakchi S, Puig L. Pathophysiology of Generalized Pustular Psoriasis. Am J Clin Dermatol. 2022 Jan;23(Suppl 1):13-19. doi: 10.1007/s40257-021-00655-y. Epub 2022 Jan 21. PMID: 35061228; PMCID: PMC8801405.
39.    Rivera-Díaz R, Daudén E, Carrascosa JM, Cueva P, Puig L. Generalized Pustular Psoriasis: A Review on Clinical Characteristics, Diagnosis, and Treatment. Dermatol Ther (Heidelb). 2023 Mar;13(3):673-688. doi: 10.1007/s13555-022-00881-0. Epub 2023 Jan 13. PMID: 36635445; PMCID: PMC9836924.
40.    Bachelez H. Pustular psoriasis and related pustular skin diseases. Br J Dermatol. 2018 Mar;178(3):614-618. doi: 10.1111/bjd.16232. Epub 2018 Jan 15. PMID: 29333670.
41.    Murakami M, Terui T. Palmoplantar pustulosis: Current understanding of disease definition and pathomechanism. J Dermatol Sci. 2020 Apr;98(1):13-19. doi: 10.1016/j.jdermsci.2020.03.003. Epub 2020 Mar 14. PMID: 32201085.
42.    Kharawala S, Golembesky AK, Bohn RL, Esser D. The clinical, humanistic, and economic burden of palmoplantar pustulosis: a structured review. Expert Rev Clin Immunol. 2020 Mar;16(3):253-266. doi: 10.1080/1744666X.2019.1708194. Epub 2020 Feb 19. PMID: 32073337.
43.    Maliyar K, Crowley EL, Rodriguez-Bolanos F, O'Toole A, Gooderham MJ. The Use of Biologic Therapy in the Treatment of Acrodermatitis Continua of Hallopeau: A Review. J Cutan Med Surg. 2019 Jul/Aug;23(4):428-435. doi: 10.1177/1203475419836435. Epub 2019 Apr 2. PMID: 30938189.
44.    Smith MP, Ly K, Thibodeaux Q, Bhutani T, Liao W, Beck KM. Acrodermatitis continua of Hallopeau: clinical perspectives. Psoriasis (Auckl). 2019 Aug 9;9:65-72. doi: 10.2147/PTT.S180608. PMID: 31497529; PMCID: PMC6691962.
45.    Galluzzo M, D'Adamio S, Teoli M, Bianchi L, Talamonti M. Biologic therapy for acrodermatitis continua of Hallopeau: Successful treatment with secukinumab and review of the literature. Dermatol Ther. 2019 May;32(3):e12899. doi: 10.1111/dth.12899. Epub 2019 Apr 29. PMID: 30969010; PMCID: PMC6618131.
46.    Potestio L, Camela E, Cacciapuoti S, Fornaro L, Ruggiero A, Martora F, et al. Biologics for the Management of Erythrodermic Psoriasis: An Updated Review. Clin Cosmet Investig Dermatol. 2023 Aug 4;16:2045-2059. doi: 10.2147/CCID.S407813. PMID: 37560255; PMCID: PMC10408653.
47.    Lo Y, Tsai TF. Updates on the Treatment of Erythrodermic Psoriasis. Psoriasis (Auckl). 2021 Jun 9;11:59-73. doi: 10.2147/PTT.S288345. PMID: 34136373; PMCID: PMC8200157.
48.    Reynolds KA, Pithadia DJ, Lee EB, Liao W, Wu JJ. A systematic review of treatment strategies for erythrodermic psoriasis. J Dermatolog Treat. 2021 Feb;32(1):49-55. doi: 10.1080/09546634.2019.1689228. Epub 2019 Nov 12. PMID: 31682547.
49.    Reynolds KA, Pithadia DJ, Lee EB, Wu JJ. Treatments for inverse psoriasis: a systematic review. J Dermatolog Treat. 2020 Dec;31(8):786-793. doi: 10.1080/09546634.2019.1620912. Epub 2019 May 31. PMID: 31100992.
50.    Micali G, Verzì AE, Giuffrida G, Panebianco E, Musumeci ML, Lacarrubba F. Inverse Psoriasis: From Diagnosis to Current Treatment Options. Clin Cosmet Investig Dermatol. 2019 Dec 31;12:953-959. doi: 10.2147/CCID.S189000. PMID: 32099435; PMCID: PMC6997231.
51.    Knabel M, Mudaliar K. Histopathologic features of inverse psoriasis. J Cutan Pathol. 2022 Mar;49(3):246-251. doi: 10.1111/cup.14142. Epub 2021 Oct 19. PMID: 34611907.
52.    Ocampo D V, Gladman D. Psoriatic arthritis. F1000Res. 2019 Sep 20;8:F1000 Faculty Rev-1665. doi: 10.12688/f1000research.19144.1. PMID: 31583079; PMCID: PMC6758836.
53.    Perez-Chada LM, Merola JF. Comorbidities associated with psoriatic arthritis: Review and update. Clin Immunol. 2020 May;214:108397. doi: 10.1016/j.clim.2020.108397. Epub 2020 Mar 27. PMID: 32229290.
54.    Karmacharya P, Chakradhar R, Ogdie A. The epidemiology of psoriatic arthritis: A literature review. Best Pract Res Clin Rheumatol. 2021 Jun;35(2):101692. doi: 10.1016/j.berh.2021.101692. Epub 2021 May 18. PMID: 34016528.
55.    Smith CH, Barker JN. Psoriasis and its management. Bmj. 2006 Aug 17;333(7564):380-4. doi: https://doi.org/10.1136/bmj.333.7564.380
56.    Young M, Aldredge L, Parker P. Psoriasis for the primary care practitioner. J Am Assoc Nurse Pract. 2017 Mar;29(3):157-178. doi: 10.1002/2327-6924.12443. Epub 2017 Feb 23. PMID: 28233460.
57.    Alhammad IM, Aseri AM, Alqahtani SAM, Alshaebi MF, Alqahtani SA, Alzahrani RA, et al. A Review on Updates in Management and Treatment of Psoriasis. Arch Pharm Pract. 2021;12(1):74-8. https://doi.org/10.51847/g6sNNo5abA
58.    Dutta S, Chawla S, Kumar S. Psoriasis: A review of existing therapies and recent advances in treatment. J Rational Pharmacother Res. 2018;4(1):12-23.
59.    Rendon A, Schäkel K. Psoriasis Pathogenesis and Treatment. Int J Mol Sci. 2019 Mar 23;20(6):1475. doi: 10.3390/ijms20061475. PMID: 30909615; PMCID: PMC6471628.
60.    Her M, Kavanaugh A. A review of disease activity measures for psoriatic arthritis: what is the best approach? Expert Rev Clin Immunol. 2014 Sep;10(9):1241-54. doi: 10.1586/1744666X.2014.943663. Epub 2014 Aug 4. PMID: 25088300.
61.    Pariser DM, Bagel J, Gelfand JM, Korman NJ, Ritchlin CT, Strober BE, et al. National Psoriasis Foundation clinical consensus on disease severity. Arch Dermatol. 2007 Feb;143(2):239-42. doi: 10.1001/archderm.143.2.239. PMID: 17310004.
62.    Gisondi P, Del Giglio M, Girolomoni G. Treatment Approaches to Moderate to Severe Psoriasis. Int J Mol Sci. 2017 Nov 16;18(11):2427. doi: 10.3390/ijms18112427. PMID: 29144382; PMCID: PMC5713395.
63.    Maul JT, Anzengruber F, Conrad C, Cozzio A, Häusermann P, Jalili A, et al. Topical Treatment of Psoriasis Vulgaris: The Swiss Treatment Pathway. Dermatology. 2021;237(2):166-178. doi: 10.1159/000512930. Epub 2021 Jan 6. PMID: 33406520.
64.    Elmets CA, Korman NJ, Prater EF, Wong EB, Rupani RN, Kivelevitch D, et al. Joint AAD-NPF Guidelines of care for the management and treatment of psoriasis with topical therapy and alternative medicine modalities for psoriasis severity measures. J Am Acad Dermatol. 2021 Feb;84(2):432-470. doi: 10.1016/j.jaad.2020.07.087. Epub 2020 Jul 30. PMID: 32738429.
65.    Oranje AP, Marcoux D, Svensson A, Prendiville J, Krafchik B, Toole J, Rosenthal D, de Waard-van der Spek FB, Molin L, Axelsen M. Topical calcipotriol in childhood psoriasis. J Am Acad Dermatol. 1997 Feb;36(2 Pt 1):203-8. doi: 10.1016/s0190-9622(97)70281-0. PMID: 9039169.
66.    Lee HJ, Kim M. Challenges and Future Trends in the Treatment of Psoriasis. Int J Mol Sci. 2023 Aug 28;24(17):13313. doi: 10.3390/ijms241713313. PMID: 37686119; PMCID: PMC10487560.
67.    van de Kerkhof PC. An update on topical therapies for mild-moderate psoriasis. Dermatol Clin. 2015 Jan;33(1):73-7. doi: 10.1016/j.det.2014.09.006. PMID: 25412784.
68.    Nakamura M, Farahnik B, Bhutani T. Recent advances in phototherapy for psoriasis. F1000Res. 2016 Jul 13;5:F1000 Faculty Rev-1684. doi: 10.12688/f1000research.8846.1. PMID: 27499849; PMCID: PMC4946393.
69.    Lapolla W, Yentzer BA, Bagel J, Halvorson CR, Feldman SR. A review of phototherapy protocols for psoriasis treatment. J Am Acad Dermatol. 2011 May;64(5):936-49. doi: 10.1016/j.jaad.2009.12.054. Epub 2011 Mar 22. PMID: 21429620.
70.    Richard EG, Hönigsmann H. Phototherapy, psoriasis, and the age of biologics. Photodermatol Photoimmunol Photomed. 2014 Feb;30(1):3-7. doi: 10.1111/phpp.12088. Epub 2013 Dec 3. PMID: 24313462.
71.    Racz E, Prens EP. Phototherapy and photochemotherapy for psoriasis. Dermatol Clin. 2015 Jan;33(1):79-89. doi: 10.1016/j.det.2014.09.007. PMID: 25412785.
72.    Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020 May 19;323(19):1945-1960. doi: 10.1001/jama.2020.4006. PMID: 32427307.
73.    Jiang Y, Chen Y, Yu Q, Shi Y. Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities. BioDrugs. 2023 Jan;37(1):35-55. doi: 10.1007/s40259-022-00569-z. Epub 2023 Jan 2. PMID: 36592323; PMCID: PMC9837020.
74.    Campanati A, Paolinelli M, Diotallevi F, Martina E, Molinelli E, Offidani A. Pharmacodynamics OF TNF α inhibitors for the treatment of psoriasis. Expert Opin Drug Metab Toxicol. 2019 Nov;15(11):913-925. doi: 10.1080/17425255.2019.1681969. Epub 2019 Oct 29. PMID: 31623470.
75.    Reid C, Griffiths CEM. Psoriasis and Treatment: Past, Present and Future Aspects. Acta Derm Venereol. 2020 Jan 30;100(3):adv00032. doi: 10.2340/00015555-3386. PMID: 31971601; PMCID: PMC9128930.
76.    Wcisło-Dziadecka D, Kaźmierczak A, Grabarek B, Zbiciak-Nylec M, Brzezińska-Wcisło L. Are new variants of psoriasis therapy (IL-17 inhibitors) safe? Int J Dermatol. 2019 Dec;58(12):1360-1365. doi: 10.1111/ijd.14509. Epub 2019 Jun 13. PMID: 31192456.
77.    Ghoreschi K, Balato A, Enerbäck C, Sabat R. Therapeutics targeting the IL-23 and IL-17 pathway in psoriasis. Lancet. 2021 Feb 20;397(10275):754-766. doi: 10.1016/S0140-6736(21)00184-7. Epub 2021 Jan 27. PMID: 33515492.
78.    Ten Bergen LL, Petrovic A, Krogh Aarebrot A, Appel S. The TNF/IL-23/IL-17 axis-Head-to-head trials comparing different biologics in psoriasis treatment. Scand J Immunol. 2020 Oct;92(4):e12946. doi: 10.1111/sji.12946. PMID: 32697374.
79.    Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T. Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis. Hum Vaccin Immunother. 2017 Oct 3;13(10):2247-2259. doi: 10.1080/21645515.2017.1356498. PMID: 28825875; PMCID: PMC5647990.
80.    Hoffman MB, Hill D, Feldman SR. Current challenges and emerging drug delivery strategies for the treatment of psoriasis. Expert Opin Drug Deliv. 2016 Oct;13(10):1461-73. doi: 10.1080/17425247.2016.1188801. Epub 2016 May 25. PMID: 27164301.
81.    Sun X, Cui Z, Wang Q, Liu L, Ding X, Wang J, Cai X, Li B, Li X. Formation and clinical effects of anti-drug antibodies against biologics in psoriasis treatment: An analysis of current evidence. Autoimmun Rev. 2024 Apr;23(4):103530. doi: 10.1016/j.autrev.2024.103530. Epub 2024 Mar 17. PMID: 38499168.
82.    Kvist-Hansen A, Hansen PR, Skov L. Systemic Treatment of Psoriasis with JAK Inhibitors: A Review. Dermatol Ther (Heidelb). 2020 Feb;10(1):29-42. doi: 10.1007/s13555-019-00347-w. Epub 2019 Dec 31. PMID: 31893355; PMCID: PMC6994544.
83.    Balogh EA, Bashyam AM, Ghamrawi RI, Feldman SR. Emerging systemic drugs in the treatment of plaque psoriasis. Expert Opin Emerg Drugs. 2020 Jun;25(2):89-100. doi: 10.1080/14728214.2020.1745773. Epub 2020 Mar 31. PMID: 32192366.
Trends in Pharmaceutical Sciences and Technologies
Volume 11, Issue 2
June 2025
Pages 127-142

Files

Share

How to cite

Statistics